Eckert & Ziegler SE (MIL:1EUZ) Cash And Cash Equivalents : €118.2 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Eckert & Ziegler SE Cash And Cash Equivalents?

Eckert & Ziegler SE's quarterly cash and cash equivalents increased from Jun. 2024 (€76.63 Mil) to Sep. 2024 (€97.63 Mil) and increased from Sep. 2024 (€97.63 Mil) to Dec. 2024 (€118.22 Mil).

Eckert & Ziegler SE's annual cash and cash equivalents declined from Dec. 2022 (€82.70 Mil) to Dec. 2023 (€68.00 Mil) but then increased from Dec. 2023 (€68.00 Mil) to Dec. 2024 (€118.22 Mil).

Eckert & Ziegler SE Cash And Cash Equivalents Historical Data

The historical data trend for Eckert & Ziegler SE's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eckert & Ziegler SE Cash And Cash Equivalents Chart

Eckert & Ziegler SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

87.48

93.66

82.70

68.00

118.22

Eckert & Ziegler SE Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															68.00	66.27	76.63	97.63	118.22

Eckert & Ziegler SE Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Eckert & Ziegler SE (MIL:1EUZ) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Eckert & Ziegler SE Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Eckert & Ziegler SE's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Eckert & Ziegler SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eckert & Ziegler SE (MIL:1EUZ) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

EUZd:UK 0NZY:UK EUZ:Germany EUZG:Austria

Address

Robert-Rossle-Street 10, Berlin, BB, DEU, 13125

Website

https://www.ezag.com

Eckert & Ziegler SE is a provider of isotope technology for medical, scientific, and industrial use. It is predominantly engaged in the business of cancer therapy, industrial radiometry, and nuclear medical imaging. The company's segments are Medical, Isotope Products, and Other. The Isotope Products segment which generates key revenue, manufactures and distributes standards and radiation sources for medical and industrial purposes. The Medical segment provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. The Other segment comprises the items of the holding company. Geographically, the company generates a majority of its revenue from Europe and the rest from North America, Asia/Pacific, and other regions.

Eckert & Ziegler SE Headlines

No Headlines